Signaling defects and functional impairment in T-cells from cervical cancer patients

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 6, 2009, Pages 667-673

  Cheriyan, Vino T ^a   Krishna, Smriti M ^a   Kumar, Aswin ^a   Jayaprakash, Puthuveetil Govindan ^a   Balaram, Prabha ^a,b  

^a REGIONAL CANCER CENTRE   (India)

^b INSTITUTE FOR RESEARCH IN MOLECULAR MEDICINE INFORMM   (Malaysia)

Author keywords

Cervical cancer; Immunomodulation; Signal transduction; T lymphocyte

Indexed keywords

CD3 ANTIBODY; CD3 ANTIGEN; CD3 EPSILON ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN; PROTEIN KINASE C; PROTEIN KINASE ZAP 70; PROTEIN P56; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ZETA CHAIN; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; UNCLASSIFIED DRUG;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; CANCER PATIENT; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL NUCLEUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; FUNCTIONAL DISEASE; GENE TRANSLOCATION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MITOGENESIS; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE; UTERINE CERVIX CANCER; WESTERN BLOTTING;

ANTIGENS, CD; ANTIGENS, CD3; CELL DIVISION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MIDDLE AGED; NEOPLASM STAGING; T-LYMPHOCYTES; UTERINE CERVICAL NEOPLASMS;

EID: 73649097617     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0660     Document Type: Article

References (30)

1. Levey DL, Srivastava PK. Alterations in T cells of cancerbearers: Whence specificity. Immunol Today 1996;17:365.
2. Balaram P, Pillai MR, Abraham T. Immunology of premalignant and malignant conditions of the oral cavity: II. Circulating immune complexes. J Oral Pathol, 1987;16:389.
3. Balaram P, Vasudevan DM. Quantitation of Fc-receptorbearing T lymphocytes (TG and TM) in oral cancer. Cancer 1983;52:1837.
4. Pillai MR, Balaram P, Nair K. Role of immune response in the prognosis of carcinoma of the uterine cervix: Can in vitro analysis provide better framework for more effective management? Tumori 1987;78:87.
5. Balaram P, Kumari TV, Vasudevan DM. Leukocyte adherence inhibition assay (LAI) in cancer of the oral cavity. Eur J Cancer Clin Oncol 1984;20:891.
6. Pillai MR, Balaram P, Abraham T, et al. Natural cytotoxicity and serum blocking effects in malignant cervical neoplasia. Am J Reprod Immunol Microbiol 1988;16:159.
7. Pillai MR, Prabha B, Kannan S, et al. Interferon activation of latent natural killer cells and alteration in kinetics of target cell lysis: Clinical implications for oral precancerous lesions. Oral Surg Oral Med Oral Pathol 1990;70:458.
8. Pillai MR, Balaram P, Chidambaram S, et al. Development of an immunological staging system to prognosticate disease course in malignant cervical neoplasia. Gynaecol Oncol 1990;37:200.
9. Hanna N. The role of natural killer cells in the control of tumor growth and metastasis. Bio Chem Biophys Acta 1986; 780:213.
10. Grimm EA, Thomas JA, Bonavida B. Mechanism of cellmediated cytotoxicity at the single-cell level: II. Evidence for first-order kinetics of T-cell-mediated cytotoxicity and heterogeneity of lytic rate. J Immunol 1979;123:2870.
11. Van de Grind RJ, Ronteltap CPM, Gravekamp C, et al. Interferon beta and recombinant IL-2 can enhance, but by differential pathways, the nonspecific cytolytic potential of T3 natural killer cell-derived clones rather than that of T3 clones. J Immunol 1986;136:1700.
12. Lai P, Rabinowich H, Crowley-Nowich PA, et al. Alteration in expression and function of signal transducing proteins in tumor-associated T and NK cells in patients with ovarian carcinoma. Clin Cancer Res 1996;2:161.
13. Zea AH, Curti BD, Longo DL, et al. Alterations in T-cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995;1:1327.
14. Matsuda M, Peterson M, Lenkei R, et al. Alterations in the signal transducing molecules of T cells and NK cells in colorectal tumor-infiltrating gut mucosal and peripheral lymphocytes: Correlation with the stage of the disease. Int J Cancer 1995;61:765.
15. Wang Q, Stanley J, Kudoh S, et al. T cells infiltrating non-Hodgkin's B-cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor=CD3- associated kinases are present. J Immunol 1995;155:1382.
16. Kurt RA, Urba WJ, Smith JW, et al. Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules. Int J Cancer 1998;78:16.
17. Shibuya TY, Nugyen N, McLaren CE, et al. Clinical significance of poor CD3 response in head and neck cancer. Clin Can Res 2002;8:745.
18. Buggins AG, Milojkovic D, Arno MJ, et al. Microenvironment produced by acute myeloid leukemia cells prevents T Cell activation and proliferation by inhibition of NF-κβ, c-Myc, and pRb pathways. J Immunol 2001;167:6021.
19. Choi SH, Chung EJ, Whang DY, et al. Alteration of signaltransducing molecules in tumour-infiltrating lymphocytes and peripheral blood lymphocytes from human colorectal carcinoma. Cancer Immunol Immunother 1998;45:299.
20. Sobin LH, Wittekind C. (Eds.). TNM Classification of Malignant Tumours, 6th ed. Geneva, Switzerland: UICC, Internation Union against Cancer, 2002;155.
21. Riss TL, Moravec RA. Comparison of MTT, XTT, and a noval tetrazolium compound MTS for in vitro proliferation and chemosensitivity assays. Mol Biol Cell 1992;3(Suppl): 184a.
22. Uchida A, Mucksche M. Lysis of fresh human tumour cells by autologous peripheral blood and pleural effusion. Int J Cancer 1983;32:37.
23. McKallip R, Li R, Ladisch S. Tumor gangliosides inhibit the tumor-specific immune response. J Immunol 1999;163: 3718.
24. Taylor DD, Edwards RP, Case CR, et al. Modulation of CD3- zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients. Gynecol Oncol 2004;94:54.
25. Riccobon A, Gunelli R, Ridolfi R, et al. Immunosuppression in renal cancer: Differential expression of signal transduction molecules in tumor-infiltrating, near-tumor tissue, and peripheral blood lymphocytes. Cancer Invest 2004;22:871.
26. Kuss I, Rabinowich H, Gooding W, et al. Expression of zeta in T-cells prior to interleukin-2 therapy as a predictor of response and survival in patients with ovarian carcinoma. Cancer Biother Radiopharm 2002;17:631.
27. Schmielau J, Nalesnik MA, Finn OJ. Suppressed T-cell receptor zeta-chain expression and cytokine production in pancreatic cancer patients. Clin Cancer Res 2001;7(3 Suppl): 933s.
28. Whiteside TL. Downregulation of zeta-chain expression in T cells: A biomarker of prognosis in cancer? Cancer Immunol Immunother 2004;53:865.
29. Whteside TL. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 1999;48: 346.
30. Whiteside TL. Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects. Adv Exp Med Biol 1998;451:167.